Objective This study was aimed to investigate the potential of formulated valproic acid-encapsulated nanoemulsion (VANE) to improve the brain bioavailability of valproic acid (VPA). Methods Valproic acid-encapsulated nanoemulsions were formulated and physically characterised (osmolarity, viscosity, drug content, drug encapsulation efficiency). Further investigations were also conducted to estimate the drug release, cytotoxic profile, in-vitro blood-brain barrier (BBB) permeability, pharmacokinetic parameter and the concentration of VPA and VANE in blood and brain. Key findings Physical characterisation confirmed that VANE was suitable for parenteral administration. Formulating VPA into nanoemulsion significantly reduced the cytotoxicity of VPA. In-vitro drug permeation suggested that VANEs crossed the BBB as freely as VPA. Pharmacokinetic parameters of VANE-treated rats in plasma and brain showed F3 VANE had a remarkable improvement in AUC, prolongation of half-life and reduction in clearance compared to VPA. Given the same extent of in-vitro BBB permeation of VPA and VANE, the higher bioavailability of VANE in brain was believed to have due to higher concentration of VANE in blood. The brain bioavailability of VPA was improved by prolonging the half-life of VPA by encapsulating it within the nanoemulsion-T80. Conclusions Nanoemulsion containing VPA has alleviated the cytotoxic effect of VPA and improved the plasma and brain bioavailability for parenteral delivery of VPA.
Introduction
Valproic acid (VPA) is a simple branched monocarboxylic acid molecule. It has a broad spectrum of efficacy being widely used as a treatment in all types of seizures and is especially effective in the treatment of idiopathic generalised seizures. [1] VPA is also known to be carried into the brain via organic anion transporter located at the bloodbrain barrier (BBB) layer. [2] However, the bioavailability of VPA in the brain is low. In spite of its wide spectrum of activity, it has many potentially serious side effects and is problematic when administered intravenously. Hepatotoxicity is a rare but well-documented side effect of valproic acid. One proposed reason is that drug becomes trapped in reticuloendothelial system (RES) producing metabolites such as 4-ene-VPA, which has possible involvement in idiosyncratic hepatotoxicity incidence. [3] A rat study reported the beta oxidation of 4-ene-VPA to reactive intermediate such as 2-propy-2, 4-pentadienoic acid (2, 4-diene VPA) had utilised large amount of mitochondrial glutathione. [4] Glutathione is important to reduce the oxidative modification which eventually reduced cell death. [5] Conclusively, greater uptake of VPA by RES means higher incidence of side effect and less drug available for therapeutic effects. On the other hand, while the brain uptake of VPA is efficient, it is limited by the low bioavailability in blood. [2] Hence, an improvement in drug delivery in the brain needs can be addressed by improving the bioavailability of VPA in the blood without elevating the treatment dose. Factors that affect the plasma exposure of drug/ nanocarrier after administration are rapidly cleared by reticuloendothelial system (RES) such as Kupffer cells in liver. [6] The use of hydrophilic surfactant such as Tween-80 has been shown to prolonge the circulation time of nanoparticles in the blood by decreasing the chance of being captured by RES. [7, 8] In view of clinical importance of VPA, alternative formulations such as nanostructured lipid carriers [9] and hydrogel nanoparticles [10] have been developed. However, there is a relative lack of studies examining cytotoxicity or in-vivo distribution. Nanoemulsions present a number of potential benefits for drug delivery including the ability to protect drugs from enzymatic degradation [11] and to prolong the circulation time in vivo. [12] In a study comparing the nanoemulsion with other nanocarrier such as nanostructured lipid carriers and solid lipid nanoparticles, nanoemulsion improved the brain bioavailability by prolonging the circulation time of it in the brain. This was likely due to flexible structure of it as explained in Wen et al. study. [12] Longer chain fatty acid nanoemulsion can prolong the circulation time of drug within the blood compared to shorter chain fatty acid nanoemulsion. [13] Hence, safflower seed oil and medium chain triglyceride were used in the formulation of VANE with the intention to prolong its blood circulation time compared to VPA which is a short-chain fatty acid. Furthermore, safflower seed oil can also improve the transport of drug across the BBB because it contains 70-87% of linoleic acid. [14] Also, high amounts of PUFA render higher chances of the nanoemulsion to be taken up by the brain in other study. [15] Therefore, in this study, the physicochemical properties and pharmacokinetic profile of formulated valproic acidencapsulated nanoemulsions (VANE) were studied in continuation of previous preliminary studies to further investigate its potential in delivering VPA to the brain. [16] Encapsulation of VPA within nanoemulsion is expected to reduce the clearance of VPA in plasma, thereby increasing its potential to permeate across the BBB.
Materials and Methods

Materials
Lecithin, safflower seed oil, alpha-tocopherol, valproic acid and Tween-80 were purchased from Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany. Medium chain triglyceride was obtained from Huls, Marl, Germany. Centrisart tubes which consist of filter membranes (molecular weight cutoff 20 000 Da) were bought from Sartorius, Goettingen, Germany. Human cerebral microvascular endothelial cells (hCMEC/D3) were kindly provided by Dr. Pierre-Olivier Couraud (Institut Cochin, INSERM, Paris, France). Endothelial basal medium-2 (EBM-2) and bullet kits were supplied by Life Technologies, Camarillo, California, USA. Normal human astrocytes (CC-2565), astrocytes basal medium and amphotericin B were purchased from Lonza Group Ltd., GB-Slough , Berkshire, UK. Pool human serum (PHS) was obtained from Life Technologies. Poly-l-lysine was bought from ScienCell, Carlsbad, California, USA. Transwell polyester insert was purchased from Corning Life Sciences, MA, Tewksbury, Massachusetts, USA. Collagen type IV and fibronectin were purchased from SigmaAldrich, St. Louis, Missouri, USA. Dexamethasone (DEX), RO (phosphodiesterase inhibitor) and cAMP analogue (CPT-cAMP) were obtained from Sigma-Aldrich.
Formulation of valproic acid-encapsulated nanoemulsion
The formulation of two VANEs (F3 and F4) was previously studied and prepared by coarse homogenisation followed by the optimised ultrasonication method. [16] The processing parameters of ultrasonicator to formulate VANE were studied with response surface methodology (centralcomposite design). The effect of oil phase and oil-to-drug ratio on droplet size, polydispersity index and zeta potential of formulated NE were studied. Out of a total of four formulations, F3 and F4 VANE were selected as their droplet size and polydispersity index were more suitable than the other two formulations. All the aforementioned studies, transmission electron microscope and long-term stability studies were reported in Tan et al. [16] paper.
Characterisation of valproic acidencapsulated nanoemulsion
Measurement of viscosity, osmolality and pH
The viscosity of both VANE was determined by using Brookfield viscometer (Model: DV II + Pro; Brookfield Engineering Laboratories Inc., Middleborough, MA, USA) coupled to spindle CPE 41. The speed of the spindle was adjusted to 10 rpm. The measurement of both VANE's osmolality was determined, using an Osmometer (Model 3320; Advanced Instruments Inc. Norwood, Massachusetts, USA), by the freezing-point method according to the manufacturer's instructions. The pH of the both formulated VANE was measured using a pH meter (Sartorius PB-11, Kuala Lumpur, Malaysia) with a microelectrode. All tests were performed at a temperature of 25 AE 0.5°C.
Drug content study
Valproic acid content in VANE was determined by highperformance liquid chromatography (HPLC). Before HPLC, VANE was diluted, first, with acetonitrile (1 : 10 ratio) and subsequently further diluted with mobile phase (1 : 10 ratio).
Drug entrapment study
The entrapment efficiency of the VANE was determined by measuring the concentration of the free VPA in the aqueous phase. The aqueous phase was separated by ultrafiltration, using centrisart tubes which contained filter membranes at the base of the sample recovery chamber (molecular weight cut-off 20 000 Da where Wt refers to amount
Drug release assay
The VPA release from the VANE was measured using a Franz diffusion cell (PermeGear Inc., Hellertown, PA, USA). The dialysis membrane was soaked in phosphatebuffered saline (pH 7.4) overnight before it was mounted between the donor and receptor compartments. The molecular weight cut-off is 12 000 Da. The donor medium consisted of 1 ml of VANE containing VPA. The receptor medium was filled with 30% ethanol in pH 7.4 buffer to maintain the sink condition during the experiments as demonstrated in Li et al. [17] Besides, that dialysis membrane is resistant to ethanol and even other stronger solvent such as DMSO which is reported and used in the dialysis method of Errico et al. [18] Previous studies have demonstrated the integrity of the dialysis membrane up to 40% ethanol. [19] The stirring rate and temperature were kept at 500 rpm and 37.0 AE 0.2°C using a circulating water bath. At appropriate intervals, 700 ll aliquots of the receptor medium were withdrawn and subjected to HPLC to quantify the amount of VPA. Drug release profiles for both of the nanoemulsion were visualised by plotting the cumulative percentage drug release against time.
In-vitro studies
Cell culture
Only passage 20-32 of hCMEC/D3 cells were grown in EBM-2 and bullet kits containing supplements, herein referred to EGM-2 because the phenotype of hCMEC/D3 cells was reported to be preserved up to P33. [20] Passages 1-10 of CC-2565 cells were grown in AGM supplemented with 10% (v/v) PHS and 1 lg/ml of amphotericin B. All cells were cultured in an incubator with 5% carbon dioxide, 95% saturated air atmosphere at 37°C. Cell culture media were changed every 2-3 days.
Cytotoxicity studies (MTT assay)
Cytotoxicity was determined by the tetrazolium dye (MTT) colorimetric assay. MTT (5 mg/ml) was dissolved in PBS. Ten thousand hCMEC/D3 cells were cultured in each of 96-well plates and were exposed to various concentration (0.4, 0.8, 1.2, 1.6 and 2 mg/ml) of free drugs (VPA), unloaded (BNE) and VPA-loaded nanoemulsion (F3 VANE and F4 VANE) for 24 and 48 h. At the end of treatment, the media containing treatment were aspirated. MTT dye solution (1 mg/ml in cell medium) was added and was incubated for 4 h. Formazen dispersion formed was removed and analysed by microplate reader (Biotek EL 311; BioTek Instruments Inc., Winooski, VT, USA) at 550 nm with a reference wavelength of 630 nm. Positive control was cells that were not exposed to any treatment. The metabolic activity of each well was determined by MTT assay and compared to those of untreated cells.
The fractional absorbance was calculated by the following formula:
Cell viability ð%Þ ¼ Absorbance value of sample À Absorbance value of blank Absorbance value of control À Absorbance value of blank Â 100 ð2Þ
Microscopic study
The morphology and viability of unstained cells were observed under an inverted phase contrast Primovert microscope (Carl Zeiss, Oberkochen, Germany).
Construction of in-vitro BBB model
Coculture model with hCMEC/D3 and CC-2565 was used in the BBB in-vitro drug permeation study. Slight modifications of methods from Poller et al. and Hatherell et al. [21] were used in the construction of this in-vitro model. Polyl-lysine (2 lg/cm 2 ) was incubated for at least 45 min and rinsed off on the basal side of the transwell polyester insert before astrocytes (4 9 10 4 /cm 2 ) were seeded on the basal side. On the fifth day, the apical side of the transwell insert was coated with 50 ll of collagen type IV (10 lg/cm 2 ) and fibronectin (5 lg/cm 2 ) (70 : 30; v/v) and was rinsed off before hCMEC/D3 (6 9 10 5 cells/cm 2 ) were cultured at the apical side of the transwell insert. The day when the endothelial cells were seeded was counted as Day 0. The EGM-2 media was replaced by enhanced media (5 lM of dexamethasone (DEX), 8.75 lM of RO (phosphodiesterase inhibitor) and 125 lM of cAMP analogue (CPT-cAMP) in EGM-2 on Day 2. Drug permeation analysis was carried out on Day 5 as depicted in Figure 1 . The drug permeation studies of in-vitro BBB model utilising hCMEC/D3 cells were studied and validated in Poller et al. [22] In-vitro drug permeation study Before drug permeation started, transendothelial electrical resistance (TEER) value was measured with an electrode chamber connected to an EVOM resistance meter (World Precision Inst. Inc., Sarasota, Florida, USA) to evaluate the integrity of the BBB layer. At 0 min, VPA, F3 VANE and F4 VANE formulation were dispensed accordingly to get a final concentration of 100 lg/ml of VPA in the apical compartment of the transwell inserts. Consecutively, the AGM solution was collected at designated time points. Drug permeation for all the three compounds was measured as apparent permeability value (cm/s).
The calculation of apparent permeability value (P app ) is shown below:
Whereby dC r dt is the gradient of the cumulative concentration of VPA standard drug in the basal compartment of the transwell (lg/min per ml), V r value represents the volume in the basal compartment of the transwell (0.6 ml), A represents the surface area of the membrane in the transwell insert (0.33 cm 2 ), and C 0 represents the concentration of VPA dispensed in the apical side of the transwell insert (100 lg/ml).
Animal pharmacokinetic study
Animal handling and care
This animal study was approved by The Institutional Animal Care and Use Committee (IACUC), Universiti Putra Malaysia. Sprague-Dawley rats (200 AE 20 g) were supplied by Takrif Bistari Enterprise (Selangor, Malaysia) and used in this study.
Design of treatment
On the day of experiments, groups of rats received either free VPA solution or F3 VANE (60 mg/kg) via i.p. At designated time points, four rats from each group were anaesthetised. The blood was withdrawn by cardiac puncture into pre-heparinised polypropylene tubes. Brains of the rats were quickly harvested and rinsed with deionised water. Neither perfusion nor capillary deletion was performed to remove the brain capillaries as the capillary blood volume represents only 1% of the total volume and only 0.1% of the endothelial cell volume. [23] Blood was centrifuged at 1372g for 15 min for plasma collection. [24] Supernatant was collected and stored at À80°C for further analysis. Before commencing the drug extraction, octanoic acid, which served as an internal standard, was dispensed into both brain homogenate and plasma samples. The concentration of VPA is calculated in a relative response of VPA to the amount of the octanoic acid in sample.
Pharmacokinetic and biodistribution analysis
Non-compartmental analysis was used in pharmacokinetic studies. The pharmacokinetic parameter such as area under the curve (AUC) to the last time point (AUC 0Àt ), elimination constant (K el ), maximum concentration of drug in blood plasma (C max ), time to the peak of drug in plasma (T max ), half-life (T 1/2 ), volume of distribution (V d ) and clearance (Cl) were calculated. Measurement of brain-toplasma partition coefficient (K p ) was calculated as ratio of AUC (AUC brain /AUC plasma ). The plasma and brain concentrations of VPA and F3 VANE were extrapolated from 120 min by numerically fitting an exponential curve using all the time points before 120 min.
High-performance liquid chromatography
The concentration of VPA in the sample was determined by HPLC (Waters, Milford, MA, USA). A detection and quantification method developed by Amini et al. [25] was slightly modified for determination of VPA concentration in various samples. The HPLC system (Waters) consisted of a 25-cm-long, 4-mm inner diameter stainless C18 column (Merck, Darmstadt, Germany) and a mobile phase of acetonitrilesodium dihydrogen phosphate buffer (pH 3.0; 0.05 M) (50 : 50, v/v) was used to determine VPA in non-biological samples. The flow rate was set at 0.5 ml/min, volume of injection 50 ll and temperature 25 AE 2°C. The detection wavelength used was 210 nm. The same method was used to determine VPA in biological samples except mobile phase of acetonitrile-sodium dihydrogen phosphate buffer (pH 3.0; 0.05 M) (35 : 65, v/v) was used instead. Biological analysis was run at flow rate of 1 ml/min at 40 AE 2°C temperature.
Data analysis
All values were reported as mean AE SD from at least three independent experiments. Statistical difference between two groups was analysed by Student's t-test while ANOVA, Tukey's test, was used for comparison of more than two groups. However, Kruskal-Wallis test was used to compare the significant difference between all the pharmacokinetic parameters of two groups (control and treatment group). Difference at P-value <0.05 was considered significant.
Results
Formulation of valproic acid-encapsulated nanoemulsion
The composition and optimum processing condition of ultrasonicator to produce VANE were previously studied. [16] Among them, both F3 and F4 VANE had the highest percentage of drug and were physically attractive. Hence, both of these formulations were characterised in the following studies. The physical parameters recorded are all presented in Table 1 . Xylitol was used as an osmolating agent in both of these parenteral formulations, as it has been shown to be a better osmolating agent than glycerol, [26] resulting in a reduced incidence of red blood cell haemolysis. [26] As a result, both formulations had an acceptable osmolality within the range of 285-310 mOsm/ kg and acceptable viscosity of less than 3.9 mPa/s for parenteral administration. [27, 28] Drug entrapment efficiency
High entrapment efficiency (>97%) was observed in both VA nanoemulsions (Table 1) . This might be due to higher pH condition during formulation of VPA into the nanoemulsion as described in Jones & Pearce study (1995) [29] where there was an increase of entrapment efficiency occurs when pH is higher than the pK a of drug.
Drug release assay
As described in Figure 2 , the F3 VANE had a faster release of VPA compared to F4 VANE. From 1 to 12 h, there was a significant difference in the cumulative VPA release from F3 and F4 VANE (P < 0.001). After fitting the drug release data into different kinetic models (Hixson, Higuchi, first-order and zero-order model), [30] it was determined that F3 VANE followed the Higuchi model (R 2 = 0.973) and F4 VANE followed Hixson-Croxwell release kinetic model (R 2 = 1.000).
In-vitro studies
Cytotoxicity studies
The cell viability of the hCMEC/D3 cells was significantly higher in medium of BNE and both VANE compared to free VPA solution after both 24 and 48 h of incubation at all concentrations, except concentration lesser than 150 lg/ ml (P < 0.05). For treatment of 24 h, formulation F3 Mean AE SD, n = 3.
VANE and F4 VANE portrayed less toxicity (viability ≥80%) at concentrations below 400 and 200 lg/ml, respectively (Figure 3a and 3b) , when compared to 100 lg/ml of VPA standard drug. F3 VANE was also observed to be less cytotoxic than F4 VANE which may be attributed to 49 higher of oil percentage in F3 VANE formulation as reported earlier. [16] Fang et al. [31] had excluded formulations with higher oil ratios because of the limited cytotoxic effect of formulations in their studies. In addition, Figure S1 depicts the microscopic studies of hCMEC/D3 cells under inverted phase contrast microscope following 24-h incubation.
Cells which were exposed to 10% DMSO appeared dead and were characteristically smaller and spherical in shape ( Figure S1a Figure S1c,d) on equimolar concentration treatment. Based on the cytotoxic profile, 100 lg/ml of VPA drug solution and VANE was chosen for the drug permeation study as both the drug solution and VANE had the least impact on cell viability (cell viabilities after treatment were not significantly different).
In-vitro drug permeation study
The in-vitro drug permeation studies were conducted in hCMEC/D3 and CC-2565 cell-seeded-transwell inserts immersed in cell culture medium. Intactness of the tight junction in the in-vitro BBB model before and after the treatment was assessed by measurement of Transendothelial Electrical Resistance (TEER) (Figure 4) . A significant decrease in TEER value was seen following treatment of the cells over 24 h (P < 0.005). However, there was a similar decrease in the control group, and there was no difference between the reductions of TEER value in the non-treated control group compared to both VANE formulation-treated groups (Figure 4) suggesting this was likely due to a natural loss of integrity of tight junctions between the adjacent hCMEC/D3 cells rather than the effect of formulation and drug solution. The apparent permeability of F3 VANE, and F4 VANE across the coculture BBB model was not significantly different from free VPA solution (Table 2 ). This indicates that the permeability of F3 VANE and F4 VANE crossed the in-vitro model of BBB as freely as VPA. VPA is known to cross the BBB via the organic anion transporter [2] while both of VANEs were speculated to cross the BBB via LDL-mediated endocytosis due to the presence of T80 in both of the VANE. [32] This might explain the lack of significant difference in the uptake of VPA and both of the VANEs across the in-vitro BBB model.
Pharmacokinetic and biodistribution analysis
Only F3 VANE was chosen to be investigated in-vivo study because it has higher drug content, smaller PDI, better stability and an improved toxicity profile compared to F4 VANE. Using a validated analytical HPLC method to quantify VPA in biological samples, standard curve ( Figure S2a,b) , retention time (Figure S3a,b) and semilog graph of concentration vs time ( Figure S4 ) were constructed. Plasma and brain concentrations of VPA were significantly higher in F3 VANEtreated rat compared to VPA standard-treated rat at all time points (Figure 5a,b) . On the other hand, the t 1/2 was prolonged while Cl and K el were reduced in F3 VANE-treated rat compared to VPA-solution treated rats (Tables 3 and 4) . This shows that the use of nanoemulsion was able to improve the bioavailability of VPA in the brain at all time. The K p value of VANE was also 4.38-fold higher than VPA (P < 0.05).
Discussion
Valproic acid is an effective anti-epileptic, but is low in brain bioavailability and is cytotoxic at high concentration. VANE, valproic acid-encapsulated nanoemulsion; VPA, valproic acid. The hCMEC/D3 and CC-2565 cell was used in the constructed in-vitro blood-brain barrier model across. Mean AE SD, n = 3. However, this study has demonstrated that formulating VPA in nanoemulsion significantly reduced the cellular toxicity and increased the central concentrations of the drug. Furthermore, our studies have demonstrated VANE to be a suitable nanocarrier for parenteral administration as they had appropriate physicochemical characteristics (viscosity, osmolality, pH, droplet size and PDI).
Previous evidence would suggest that there is slower drug release from a nanoemulsion with a larger droplet size, due to the smaller surface area. [33] However, this was not the case in our study as F3 VANE had a more rapid drug release than F4 VANE although F3 VANE was larger in droplet size. This may be a result of three times lower ratio of surfactant-to-oil in F3 VANE which may have allowed more release of VPA into the aqueous phase as the surfactant layer in the oil-water interface is weaker. [34] It was interesting to note that the drug release of both nanoemulsions was not complete. This may be due to the precipitation of the drug on the membrane which was reported in Choudhury et al. [35] On the other hand, many other types of colloidal systems have reported incomplete drug release, and this is often attributed to the physical barrier of the nanocarrier. [36] Furthermore, a sustained release property of nanoemulsion could be seen as being advantageous as it will prolong the pharmacological effect of the VPA in vivo.
As demonstrated, VANE generally resulted higher levels of cell viability compared to VPA which may have been due to the controlled-release property of nanoemulsion as shown in drug release studies. This result was also in accordance with other studies whereby the cytotoxic effects of drugs were reduced by encapsulation of drug within nanocarrier. [37, 38] Concentration of 100 lg/ml of VPA is considered non-toxic as it exhibited ≥80% of cell viability [39] ; hence, it was used in assessing the permeation of VPA, F3 VANE and F4 VANE across in-vitro BBB layer.
There were improvements in several of the pharmacokinetic parameters of VPA in the blood and brain with the use of F3 VANE which are in line with other studies using nanoemulsions. [40] [41] [42] It is known that the pharmacokinetics and distribution of a drug in formulation are determined by the physicochemical properties of the nanocarrier rather than the drug itself. [24] Hence, the use of nanoemulsion has improved the systemic bioavailability of VPA (Figure 5i ) possibly due to small droplet size of F3 VANE (<150 nm). Ragelle et al. [40] compared a nanoemulsion and free fisetin solution administered i.p to mice. Their nanoemulsion had higher plasma concentration, lower elimination constant and lower clearance, similar to the results in our study. Indeed, the nanoemulsion droplet size, in Ragelle and colleagues study, 153 AE 2 nm, is equivalent to the F3 VANE developed in our study. This shows less VPA was being removed from the body when it was encapsulated within F3 VANE, resulting in a higher bioavailability of F3 VANE and longer retention times. Furthermore, the use of a surfactant Tween-80 in the nanoemulsion delayed the release of VPA into the bloodstream (Figure 2 ) and further retarded the removal of the VPA by RES. [7] The presence of T80 in F3 VANE was also likely to have resulted in reduced clearance and elimination from the blood. This is in line with other work whereby T80 reduced the clearance of etoposide from liver by 1.5-fold. [41] On the other hand, F3 VANE is made up of safflower seed oil which is rich in long-chain fatty acid while VPA drug is made up of short-chain fatty acid. Shortchain fatty acid (VPA) was known to be cleared off faster than long-chain fatty acid (F3 VANE) in blood circulation as it is not susceptible to clearance by the carnitine-dependent co-transportation system. [43] The bioavailability of the VPA in brain tissues was significantly higher in VANE-treated rats compared to VPA solution-treated rats at all time points (P < 0.001) (Figure 5b ). The improvement of brain delivery of VPA by F3 VANE was further supported by an improved of 4.38-fold of K p value in F3 VANE compared to VPA (Table 4 ). Figure 2 shows there was at least 70% of VPA still retained within the F3 VANE at first hour while Figure 5a shows the T max of VANE was at 45 min. Hence, it was believed that at least 70% of VPA was still retained and gets transported into the brain with VANE. The transportation of VANE across the BBB was believed to have been facilitated by the use of Tween-80 in NE. Tween-80 binds substantially to the apolipoprotein E (ApoE), and this ApoE is involved in the mediated transport of Tween-80-containing VANE into the brain [44] whereby ApoE interacts with the LDL receptors which are on the apical side of brain microvascular. [32] Although in-vitro drug penetration BBB shows no significant difference in VPA and VANE permeating the BBB, the brain bioavailability of F3 VANE was significantly improved (P < 0.05) ( (Figure 5b) following the prolongation of F3 VANE half-life in plasma (P < 0.05) ( Table 4 ). This shows that the brain bioavailability of VPA can be improved by encapsulating it within nanoemulsion with T80 as T80 reduced the elimination of VPA in blood significantly (P < 0.05) ( Table 4) which was also reported in other work. [41] Our study suggests a solution to increase the brain bioavailability of VPA by improving the bioavailability of free VPA in the blood without increasing the dose.
Conclusions
We have demonstrated that the cytotoxic effect of VPA was significantly reduced by formulating it within the core of NE. In-vitro BBB drug permeation study shows there were no significant difference in transportation of VPA, F3 VANE and F4 VANE across the BBB possibly due to the same mechanism of uptake. However, there was a significant improvement of the bioavailability of F3 VANE in the blood and brain compared to VPA solution. These improvements were believed to have been achieved by reducing the elimination rate of F3 VANE in the blood, thereby allowing more F3 VANE to cross the BBB as F3 VANE was mostly made up of PUFA and 2% of Tween-80.
Declaration 100 g/mL F4 VANE. (f) Growth media containing 150 g/mL of F3 VANE.(g) Growth media containing 100 g/mL F4 BNE. (h) Growth media containing 150 g/mL F3 BNE. Scale bar: 50 m. Figure S2 . Calibration curve equation and correlation of coefficient value for (a) plasma (y = 1.71 + 4.30e-004; R 2 = 0.986673) (b) brain homogenate (y = 1.71x-2.62e-003; R 2 = 0.987014). Figure S3 . Representative chromatograms of (a) a blank plasma spiked with 100 lg/ml octanoic acid as internal standard (b) blank plasma spiked with 40 lg/ml of valproic acid with 100 lg/ml octanoic acid. Figure S4 . A linear relation of log concentration of valproic acid vs time (t).
